Chapters Transcript Video Checkmate 214 Presented by Toni Choueiri, MD. Dr. Toni Choueiri shares groundbreaking 9-year results from the CHECKMATE-214 trial. Checkmate 214 is now a very famous pivotal trial in metastatic kidney cancer. It's established since 2018 for the first time, a treatment that be single agent reject TKI treatment with two immunotherapy nivolumabilumumab. We have uh seen many results and many publications, uh, from Checkmate 214, but in metastatic kidney cancer here, we presented also as part of uh An oral session at the ASCO 2025, a very successful meeting for our colleagues at the Dana-Favre. So great news for patients. We presented the final follow up, 9 years follow up. Usually we get excited with the 1st 9 years follow up uh for the combination of nivolumabilumumab, and I'm happy to say that at 9 years, over 30% of patients are still alive. I mean, when, when, when you think how we started 10 years ago or more with metastatic kidney cancer where the 5 year survival was 5%, now you have a 9 year survival of 30%. This is mind blowing. We also found no new toxicities, so there was nothing long, long term there. We found that the responses, the vast majority that we achieved the complete responses stayed. And even if the responses happened with the control arm sunnitinib, on NOIP, the responses were way more durable. Uh, this is another uh win for those patients and fair enough. Uh, current trials are trying to build. On nivolumab and ipilimab as a standard. It's two drugs and then uh one drug, nivolumab as maintenance. I'm very pleased personally with these results. They give us long term safety, long term efficacy for patients. When patients come to us at Dana-Farber in clinic, we can quote them and they ask us what's going to happen in 5 years, 7 years. We can quote them results like this. Major win for um. Uh, for kidney cancer patients, um, in the US and everywhere in the world. Published June 11, 2025 Created by Related Presenters Toni Choueiri, MD Medical Oncology View Full Profile
